Partnering and collaborations have been a critical part of Lytix Biopharma’s strategy and will continue to be an emphasis for our future growth. To date, we have developed significant scientific and commercial alliances that enable us to drive our proprietary programs forward, while retaining significant value in the downstream potential of our internal programs.

We are actively exploring alliances that complement our expertise in peptide and small molecule product development with important scientific, clinical and development capabilities. These alliances may incorporate our various technology platforms, pre-IND product candidates and small molecule development capabilities.


At Lytix, we are looking for, and open to, collaborations and partnerships for our two leading programs:

  • LTX-315, currently in Phase II clinical trials and targeting solid tumors, among them: metastatic melanoma, basal cell and squamous cell carcinoma, head and neck cancer, and breast cancer
  • LTX-401, currently in late preclinical development and targeting high unmet medical needs in tumors with deep seated lesions, particularly liver and colorectal cancer.

Discovery partnerships focused on finding the next generation of Oncolytic Molecules.




Current partnerships:

Verrica Pharmaceuticals, currently conducting a Phase II trial with LTX-315.

Verrica has a worldwide license to develop and commercialize LTX-315 for malignant and pre-malignant dermatological indications. Under the license agreement we may receive total payments of more than $110 million as signing fee and upon achievement of certain clinical, regulatory and sales milestones as well as tiered royalty payments in the double-digit teens.